The Denver Post – MiRagen Therapeutics Inc. landed $41 million in financing to bring its two lead micro ribonucleic acid molecule-targeting drug candidates to clinical trials — a big step toward the Boulder biopharmaceutical firm’s goal for an initial public offering next year. Keep reading.
